Have a feature idea you'd love to see implemented?
Let us know!
RPTX Repare Therapeutics Inc
Price (delayed)
$3.37
Market cap
$143.04M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.63
Enterprise value
$65.4M
Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled
Highlights
RPTX's debt has dropped by 52% year-on-year and by 22% since the previous quarter
RPTX's quick ratio is up by 25% year-on-year but it is down by 14% since the previous quarter
Repare Therapeutics's gross profit has plunged by 59% YoY and by 30% from the previous quarter
Repare Therapeutics's revenue has plunged by 59% YoY and by 30% from the previous quarter
Key stats
What are the main financial stats of RPTX
Market
Valuations
Earnings
Shares outstanding
42.45M
Market cap
$143.04M
Enterprise value
$65.4M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.7
Price to sales (P/S)
2.08
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.95
Revenue
$68.68M
EBIT
-$83.68M
EBITDA
-$79.44M
Free cash flow
-$80.01M
Per share
Balance sheet
Liquidity
EPS
-$1.63
Free cash flow per share
-$1.88
Book value per share
$4.8
Revenue per share
$1.62
TBVPS
$5.54
Total assets
$235.34M
Total liabilities
$31.67M
Debt
$2.18M
Equity
$203.68M
Working capital
$197.09M
Debt to equity
0.01
Current ratio
7.27
Quick ratio
6.73
Net debt/EBITDA
0.98
Margins
Efficiency
Dividend
EBITDA margin
-115.7%
Gross margin
100%
Net margin
-99.8%
Operating margin
-139.5%
Return on assets
-26.4%
Return on equity
-31.1%
Return on invested capital
-67%
Return on capital employed
-41%
Return on sales
-121.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RPTX stock price
How has the Repare Therapeutics stock price performed over time
Intraday
-1.75%
1 week
0.6%
1 month
0%
1 year
-15.54%
YTD
-53.84%
QTD
-2.03%
Financial performance
How have Repare Therapeutics's revenue and profit performed over time
Revenue
$68.68M
Gross profit
$68.68M
Operating income
-$95.79M
Net income
-$68.52M
Gross margin
100%
Net margin
-99.8%
RPTX's net margin has dropped by 114% since the previous quarter
Repare Therapeutics's operating margin has shrunk by 93% QoQ
Repare Therapeutics's gross profit has plunged by 59% YoY and by 30% from the previous quarter
Repare Therapeutics's revenue has plunged by 59% YoY and by 30% from the previous quarter
Growth
What is Repare Therapeutics's growth rate over time
Valuation
What is Repare Therapeutics stock price valuation
P/E
N/A
P/B
0.7
P/S
2.08
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.95
RPTX's EPS is down by 50% from the previous quarter
The P/B is 74% below the 5-year quarterly average of 2.7 and 46% below the last 4 quarters average of 1.3
The equity has contracted by 17% YoY and by 12% from the previous quarter
Repare Therapeutics's revenue has plunged by 59% YoY and by 30% from the previous quarter
The P/S is 57% lower than the last 4 quarters average of 4.8
Efficiency
How efficient is Repare Therapeutics business performance
RPTX's ROS has plunged by 105% from the previous quarter
The ROA has plunged by 60% from the previous quarter
RPTX's return on equity has dropped by 57% since the previous quarter
Repare Therapeutics's ROIC has decreased by 47% from the previous quarter
Dividends
What is RPTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RPTX.
Financial health
How did Repare Therapeutics financials performed over time
Repare Therapeutics's total liabilities has decreased by 44% YoY
The current ratio rose by 33% YoY but it fell by 13% QoQ
RPTX's debt is 99% smaller than its equity
RPTX's debt has dropped by 52% year-on-year and by 22% since the previous quarter
The debt to equity has dropped by 50% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.